Ralfinamide (
INN) (code names NW-1029, FCE-26742A, PNU-0154339E) is a
multimodal drug
A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed. Drugs are typically distinguished from food and substances that provide nutritional support. Consumption of drugs can be via insuffla ...
which is under investigation by
Newron Pharmaceuticals for the treatment of
neuropathic pain and other
pain conditions such as
post-operative
Surgery ''cheirourgikē'' (composed of χείρ, "hand", and ἔργον, "work"), via la, chirurgiae, meaning "hand work". is a medical specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pat ...
dental pain.
It has a relatively complex
pharmacology
Pharmacology is a branch of medicine, biology and pharmaceutical sciences concerned with drug or medication action, where a drug may be defined as any artificial, natural, or endogenous (from within the body) molecule which exerts a biochemica ...
, acting as a mixed
voltage-gated sodium channel blocker (including
Nav1.7),
,
,
and
monoamine oxidase B inhibitor
Inhibitor or inhibition may refer to:
In biology
* Enzyme inhibitor, a substance that binds to an enzyme and decreases the enzyme's activity
* Reuptake inhibitor, a substance that increases neurotransmission by blocking the reuptake of a neurotra ...
.
It has thus far progressed as far as
phase IIb
The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases ...
/
phase III clinical trials.
In 2010 it failed a phase II trial for lower back pain. Encouraging Phase II results have been announced for neuropathic pain.
Newron Announces Positive Results With Ralfinamide From Phase II Trial in Neuropathic Pain
/ref>
See also
* List of investigational analgesics
* Safinamide
Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B. SeFDA index page for NDA 207145for updates ...
, different fluorine position
* Evenamide
Evenamide () (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, which is described as an antipsychotic and is under development ...
, structurally-related antipsychotic in development
* Lacosamide
Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. It is used by mouth or intravenously.
It is available as a generic medic ...
, used for partial-onset seizures and diabetic neuropathic pain
* Ziconotide, FDA
The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food s ...
approved peptide for chronic neuropathic pain
References
External links
Ralfinamide - Newron Pharmaceuticals
Carboxamides
Analgesics
Calcium channel blockers
Monoamine oxidase inhibitors
NMDA receptor antagonists
Fluoroarenes
Sodium channel blockers
Experimental drugs
{{analgesic-stub